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Methylprednisolone-induced Toxic Hepatitis After
Intravenous Pulsed Therapy for Multiple Sclerosis Relapses
Diana Ferraro, MD,* Vincenzo G. Mirante, MD,w Luisa Losi, MD,z
Erica Villa, MD,y Anna M. Simone, MD,* Francesca Vitetta, MD,*
Lucia Federzoni, MD,* Paolo F. Nichelli, MD, PhD,*
and Patrizia Sola, MD, PhD*
Abstract: High-dose, intravenous methylprednisolone (MP) is the only
recommended first-line treatment for multiple sclerosis relapses.
However, there are increasing reports on liver toxicity induced by this
treatment regimen. We report of 4 multiple sclerosis patients with no
history of viral/metabolic liver disorders or alcohol/hepatotoxic drug
intake, who developed hypertransaminasaemia following intravenous
MP. In 2 of the patients, liver biopsy showed periportal fibrosis,
piecemeal necrosis, and inflammatory cell infiltrates. A rechallenge
test confirmed a causal association in 1 case. MP-induced liver toxicity
may be more frequent than commonly thought and it is important to
report this adverse reaction, which is potentially lethal, and to raise
awareness on the potential hepatotoxicity of corticosteroid pulses.
Key Words: liver toxicity, steroid pulses, multiple sclerosis, relapse
(The Neurologist 2015;00:000–000)
Cases of acute hepatitis related to intravenous methyl/pre-dnisolone (IVMP) therapy have previously been described
in patients treated for multiple sclerosis (MS) relapses,1–5 in a
patient with central nervous system vasculitis and in patients
with Graves ophtalmopathy. Severe steatohepatitis and liver
failure were fatal in another 3 patients treated with pre-
dnisolone for lupus erythematosus systemicus, dermatomyo-
sitis, and Graves ophtalmopathy (reviewed in Gutkowski
et al2).
We report 4 cases of liver injury following IVMP therapy
(1 g for 5 d) in patients treated for MS relapses for the first
time. All patients had normal blood chemistry before treat-
ment, they denied alcohol intake, and no concomitant medi-
cations were taken except for lisinopril in case 1. Diagnostic
work-up was normal in all patients, except for case 3 (vide
infra), and entailed serological tests for HAV, HBV, HCV,
EBV, CMVAQ2 and syphilis, dosage of antinuclear (ANA) and
antismooth muscle antibodies (ASMA), antimitochondrial
antibodies, liver-kidney microsomal antibodies, iron, serum
ferritine, blood lipid profile, serum ceruloplasmin, and liver
ultrasound.
CASE REPORTS
Case 1 (50-y-Old Female, History of Arterial
Hypertension)
Transaminases started increasing on day 4, peaked on day 8
[aspartate aminotransferase (AST): 136 U/L, alanine aminotransferase
(ALT): 355 U/L, and g-glutamyl transpeptidase (gGT): 346 U/L], and
normalized by day 24.
Case 2 (30-y-Old Female)
Transaminases started increasing on day 3, reached a peak level
on day 6 (AST: 157 U/L, ALT: 627 U/L), and returned to normal
within 2 weeks.
Case 3 (38-y-Old Woman With Autoimmune
Thyroiditis)
Transaminases peaked after 2 months (AST: 109 U/L, ALT:
260 U/L, gGT: 54 U/L) and normalized within another month. The
diagnostic work-up revealed positive ANA (1:640) and ASMA (1:80).
Case 4 (24-y-Old Woman)
IVMP was administered in February (followed by a 1-mo oral
taper), in July, and in September 2008. Transaminases were dosed
before treatment in July (AST: 211 U/L, ALT: 494 U/L) and in Sep-
tember (AST: 315 U/L, ALT: 671 U/L, gGT: 89 U/L). Abdominal
ultrasound showed liver steatosis. Liver enzymes gradually returned to
normal by November, but newly transiently increased in December
(AST: 37 U/L, ALT: 104 U/L), over the period of 1 week, following a
rechallenge with IVMP for another MS relapse.
Liver biopsy was performed in cases 3 and 4 and showed, in both
the cases, inflammatory infiltrates, focal piecemeal necrosis, periportal
fibrosis, and numerous ceroid-laden macrophages.
DISCUSSION
Drug-induced liver injury is mediated by either an intrinsic,
dose-dependent, and predictable mechanism, or by an idiosyn-
cratic, dose-independent, and unpredictable mechanism. The
clinical expression of drug-induced disease is highly variable,
including minimal and asymptomatic liver enzyme elevations,
acute or chronic hepatitis, cholestatic liver disease, and acute
liver insufficiency. Criteria favorable to a diagnosis include
exclusion of alternative causes of liver damage, demonstration of
clinical and serological improvement after dechallenge, and the
reappearance of alterations after rechallenge.6
The conjunction of clinical, laboratory, and histologic data;
the exclusion of other causes of hepatic profile changes; and the
rechallenge in 1 patient, suggest that hepatitis in our patients was
probably related to an idiosyncratic reaction to IVMP treatment
except maybe in patient 3. Patient 3 had a positivity for ANA and
ASMA and we cannot rule out an autoimmune hepatitis (AIH),
although the liver biopsy did not suggest this diagnosis, as there
have been reports of AIH developing after methylprednisolone
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(MP) treatment,7 the hypothesis being that of a rebound phe-
nomenon after discontinuation of immunosuppressive regimens.
High-dose MP is the only recommended first-line treat-
ment of MS exacerbations. Plasma exchange may be consid-
ered for patients who have not responded to MP, although only
about one third of patients are likely to respond, and there is
insufficient data to support the use of intravenous immuno-
globulins as monotherapy for MS relapses.8,9 As a con-
sequence, treatment of MS relapses becomes challenging if IV
steroids are not a safe choice. Further studies on current sec-
ond-line and third-line treatments such as plasma exchange and
intravenous immunoglobulins and on possible alternative
treatment regimens are needed.
Glucocorticoid-induced liver toxicity is probably more
frequent than it may appear and it is a known entity among
hepatologists. However, neurologists and other specialists who
are faced with exacerbations of autoimmune diseases may not
be aware of the risk of high-dose corticosteroid therapy. Con-
sidering the widespread use of short-term high-dose regimens
of corticosteroids, it is important to highlight the importance of
this possible, potentially lethal, adverse reactionAQ3 10–12 (Fig. 1).
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FIGURE 1. Liver biopsy of case 4 showing inflammatory infiltrates in the portal space and focal piecemeal necrosis. Hematoxylin and
eosin stain, magnification: 10 (A) and 20 (B).
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